|
George Poste, DVM, Ph.D. has been a member of Orchid’s Board of Directors since April 2000 and its Chairman since October 2002. Dr. Poste is the former president of research and development and chief science and technology officer at SmithKline Beecham, Plc, and current chief executive officer of Health Technology Networks. During his tenure in the pharmaceutical industry, Dr. Poste was associated with 29 successful drug and vaccine registrations in the U.S. and internationally. He is non-executive chairman of diaDexus, the joint venture in molecular diagnostics between GlaxoSmithKline and Incyte Pharmaceuticals located in Santa Clara, CA, and non-executive chairman of Structural GenomiX in San Diego. Dr. Poste also serves on the Board of Directors of Maxygen, Illumina and AdvancePCS. He was educated in England and received a degree in Veterinary Medicine in 1966 and a Ph.D. in virology in 1969 from the University of Bristol. Dr. Poste is a Fellow of the Royal Society, The Academy of Medical Sciences and the Royal College of Pathologists, and has been awarded honorary Doctorates in Science and in Law for his contributions to health research and international health policy. He is a member of the Defense Science Board of the U.S. Department of Defense, chairing the Task Force on Defense Against Bioterrorism.
George H. Poste, DVM, Ph.D., age 61, has served as a member of our Board of Directors since March 2000 and as chairman since 2002. He currently serves as director of The Biodesign Institute at Arizona State University. He is also the Chief Executive Officer of Health Technology Networks, a consulting group specializing in the impact of genetics, computing and other advanced technologies on healthcare research and development and Internet-based systems for healthcare delivery. From 1992 to 1999, Dr. Poste was President of Research and Development, Chief Science and Technology Officer and a member of the board of directors of SmithKline Beecham PLC. Dr. Poste was a non-executive chairman of diaDexus, LLC from 1997 to 2004, the joint venture in molecular diagnostics between SmithKline Beecham and Incyte Pharmaceuticals, and a non-executive chairman of Structural GenomiX from 2000 to 2004. He serves on the board of directors of Exelixis, Monsanto Company and the Molecular Profiling Institute. Dr. Poste received his degree in veterinary medicine and his Ph.D. in virology from the University of Bristol, England. He is a Board-certified pathologist and a Fellow of the Royal Society. At the time of filing of this Annual Report on Form 10-K, Dr. Poste is functioning as our Principal Executive Officer. | 